68Ga-FAPI-04: the first experience of clinical application in Russia
Open Access
- 17 January 2023
- journal article
- research article
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 13 (4) , 27-37
Abstract
INTRODUCTION: According to the literature, 68Ga-FAPI-04 has receptor specificity for malignant neoplasms with overexpression of the fibroblast activation protein and is used to visualize various types of neoplasms, in particular head and neck cancer, gastrointestinal tract, lung, breast cancer with a high contrast ratio of the tumor to the background, and may possibly become an alternative to 18F-FDG.OBJECTIVE: The results of the first experience of using PET/CT with 68Ga-FAPI-04 in Russia.MATERIALS AND METHODS: A comparative analysis of the results of 68Ga-FAPI-04 and 18F-FDG PET/CTs with an interval of 1–3 days was carried out in 13 patients (four women and nine men) with various oncological diseases, examined from February to December 2021 in Granov Russian Research Center of Radiology and Surgical Technologies.RESULTS: In all 13 patients, it was possible to identify both primary tumors and their metastases with different tracer uptake. 68Ga-FAPI PET/CT compared with 18F-FDG PET/CT revealed more metastatic foci (135 vs 127) predominantly in the liver, peritoneum, mesentery, omentum, and brain due to low background uptake in these organs. In our observation, foci of increased 68Ga-FAPI-04 uptake localized in non-enlarged retroperitoneal lymph nodes in two patients. Also, in two patients with bone metastases from bladder cancer and stomach cancer, one false positive and one false negative result was obtained with 68Ga-FAPI-04.DISCUSSION: The high uptake of 68Ga-FAPI-04 in the tumor makes it a promising tracer for many types of cancer, especially in cases, where conventional 18F-FDG PET/CT faces limitations due to its pharmacokinetics. At the same time, PET/CT with 68Ga-FAPI-04, aimed at visualizing the tumor microenvironment, may have a higher sensitivity in detecting small lesions due to the predominance of stroma in them. 68Ga-FAPI showed better results in detecting both lytic and osteoblastic bone metastases compared to 18F-FDG.CONCLUSION: 68Ga-FAPI is a promising tracer for molecular imaging of most malignant neoplasms and requires further study. 68Ga-FAPI-04 can become an addition or a full-fledged solution when other tracers have limitations.Keywords
This publication has 21 references indexed in Scilit:
- FAP: The Next Billion Dollar Nuclear Theranostics Target?Journal of Nuclear Medicine, 2020
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer PatientsJournal of Nuclear Medicine, 2019
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerJournal of Nuclear Medicine, 2019
- Fibroblast-Activating Protein: Targeting the Roots of the Tumor MicroenvironmentJournal of Nuclear Medicine, 2018
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various CancersJournal of Nuclear Medicine, 2018
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation ProteinJournal of Nuclear Medicine, 2018
- A Tumor-Imaging Method Targeting Cancer-Associated FibroblastsJournal of Nuclear Medicine, 2018
- The biology and function of fibroblasts in cancerNature Reviews Cancer, 2016
- Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapyProteomics – Clinical Applications, 2014
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012